Research programme: microbiome targeted therapeutics - Symberix

Drug Profile

Research programme: microbiome targeted therapeutics - Symberix

Alternative Names: Bacterial enzyme inhibitors - Symberix

Latest Information Update: 02 Dec 2015

Price : $50

At a glance

  • Originator Symberix
  • Class Small molecules
  • Mechanism of Action Bacterial protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gastrointestinal disorders

Most Recent Events

  • 20 Nov 2015 Preclinical trials in Gastrointestinal disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top